ARTICLE | Product Development

Long COVID therapies are starting to populate a sparse pipeline

Candidate treatments are split between therapies addressing symptoms versus hypothesized drivers

March 13, 2021 2:52 AM UTC

As Long COVID research ramps up, the first set of therapeutic candidates are either geared toward organ-centered pathology shared with other diseases, or viral and immune mechanisms that could be unifying drivers of the syndrome’s wide-ranging symptoms.

One year into the pandemic, it’s estimated that about 10% of patients who recover from SARS-CoV-2 infection are left with a grab bag of long-lasting symptoms, many of them devastatingly incapacitating...